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Objectives:
 
 To estimate relationships between medical
care expenditures in 1996 and adherence to seven
guideline-based measures for diabetes.
 
Methods and Data:
 
 Nonlinear exponential regression
analyses were used to estimate relationships between
medical care expenditures in 1996 and adherence to
guideline-based measures that year, adjusting for differ-
ences in patients’ demographics, location, plan type,
and severity of illness. Adherence to criteria regarding
physician visits, eye exams, blood sugar tests, urinaly-
sis, triglyceride tests, total cholesterol tests, and HDL
cholesterol tests was studied for 18,403 patients in 35
health plans.
 
Results:
 
 Average total medical expenditures would be
$713 higher if all patients were treated according to the
guideline-based measures in 1996, compared to what
expenditures would be if no patients were treated that
way. Average diabetes-related expenditures would be
about $322 higher. Two important exceptions to this
pattern were for adherence to the suggested frequency
of hemoglobin A1c blood sugar tests and ophthalmol-
ogy visits for dilated eye exams. Having the recom-
mended number of these tests was associated with sig-
nificantly lower total expenditures.
 
Conclusions:
 
 In general, adherence to clinical practice
guideline-based measures was more costly than deviat-
ing from those criteria, in the short-run. Perhaps expen-
ditures should be higher for many patients who are not
treated according to guidelines. Randomized studies
with more years of follow-up should be conducted to
assess whether short-term investments in guideline ad-
herence pay off with lower medical expenditures and
greater levels of health in the long term.
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Introduction
 
In recent years, many have accepted the underly-
ing premise of most clinical practice guidelines,
that better treatment will lead to better outcomes.
For diabetes, which affects about 4.5% of Ameri-
cans and accounts for about 14.6% of health care
expenditures in this country [1], the literature on
adherence to American Diabetes Association (ADA)
guidelines is small but growing. Early studies illus-
trated some variation in the likelihood that guidelines
will be met. For example, a study based on National
Health Interview Survey data by Brechner et al. [2]
showed that less than half (49%) of the patients sur-
veyed remembered having a dilated eye exam in the
last year to detect or monitor retinopathy, a major
complication leading to vision loss. A more recent
study by Beckles et al. [3], based on the 1994
Behavioral Risk Factor Surveillance System data,
showed that 61% had a dilated eye exam. The
ADA, the American College of Physicians, and the
American Academy of Ophthalmology [4] recom-
mend that all patients have at least one dilated eye
exam annually.
Another study [5] based on national survey
data suggested that the average patient had less
than two (i.e., 1.9) office-based blood glucose tests
in the last year; this is slightly below the 1990
ADA recommendations.
Center-based studies find different patterns of
adherence to guidelines than the national surveys
do. For example, a study by Miller and Hirsch [6]
showed that only 29% of the 157 patients treated
at a large university’s health clinic received a gly-
cosylated hemoglobin (i.e., blood glucose) test in a
27-month study period, and only 42% had at least
one urinalysis. ADA guidelines recommend these
tests two to four times a year for all patients. An-
other study by Peters et al. [7] noted the experi-
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ence of one large HMO system in California. They
found that 44% of the 384 patients selected for
study had one or more glycosylated hemoglobin
measures during the study year, and urinalyses
were conducted on about 48% of the patients. In
addition, total cholesterol was measured in 56%
of the patients, and 79% of the patients had at
least two face-to-face visits with a physician in the
last year. Only 6% had a documented foot exam,
and 54% had serum creatinine measurements. An-
other HMO-based study by O’Connor et al. showed
65% of the patients having at least two blood sugar
tests in the last year, while 75% had total cholesterol
test [8]. Again, ADA guidelines suggest that these
tests be conducted annually for all patients.
This rather brief review suggests that less than
half of the patients in the US are treated in accor-
dance with the ADA guideline. In addition, some
variation exists across treatment settings. Surpris-
ingly, however, guideline research has had little to
say about the impact of adherence to clinical prac-
tice guidelines on medical care expenditures. A re-
cent study pertaining to asthma [9] is one excep-
tion, but the impact of adherence to guidelines
may differ by the disease and guideline criteria
considered. Moreover, a focus on expenditures
may be of direct interest to health plans and pro-
viders who are trying their best to provide cost-
effective care.
Some speculation has been noted that lower ex-
penditures result from adhering to diabetes treat-
ment guidelines [10], but to our knowledge this is-
sue has not been addressed in rigorous research.
Self-insured employers who pay for their em-
ployee’s health care, along with other types of
payers and managed care plans, could benefit
from knowing how much they might save or
spend by following clinical practice guidelines.
Does better care cost more or less in the short run?
We investigate this issue for diabetes care in this
paper.
 
Methods
 
Data source and sample
 
This study is based upon an analytic sample of
18,403 patients enrolled in 35 health plans across
the US in 1995 and 1996. These health plans were
offered by large employers who contributed inpa-
tient, outpatient, and health plan enrollment data
to The MEDSTAT Group’s MarketScan Family of
Databases. In 1995 and 1996, information on the
inpatient and outpatient services and health plan
enrollment features were available for over 1,524
 
million covered lives in the 35 health plans. 65,641 of
these covered lives had at least one claim for services
with an accompanying diagnosis code for diabetes in
1995, leading to a period prevalence estimate of
4.3%. This group was considered for follow-up into
1996 to investigate adherence to the clinical practice
guidelines.
Of the 65,641 patients identified in 1995, only
38,923 were continuously enrolled in a health
plan for 12 months beyond the date when their
first diabetes service was noted in the claims or en-
counter records. From this group, we included
only those who had:
• At least one emergency room visit for diabetes,
or;
• At least one hospital admission for diabetes,
or;
• At least one pharmacy claim for a diabetes
medication (insulin or an oral hypoglycemic
drug); or
• Two face-to-face encounters with a health care
provider in the 12-months (beginning in 1995)
in which their first diabetes service was noted
in the database. Two encounters were required
to exclude those with diabetes-rule out diag-
noses (i.e., those with symptoms similar to dia-
betes but who were found not to have diabetes
upon further examination).
The application of these criteria led to 31,084
patients. From this group, we excluded those who
were pregnant sometime in 1995 or 1996, and
those who were not enrolled in a health plan for
all 12 months of 1996, when adherence to guide-
lines was measured. This reduced the sample to
22,775 patients. Next, we excluded those who
died sometime in 1995 or 1996 (
 
n
 
 
 

 
 38), those
over age 65 (
 
n
 
 
 

 
 908) and those for whom pay-
ment data were questionable (e.g., those who had
negative values for total expenditures). Finally, we
excluded those in HMO and capitated point-of-
service plans, since expenditure data were not
available for those people. This led to the final an-
alytic sample of 18,403 patients.
 
Using Claims Data to Measure Adherence to Clinical 
Practice Guidelines
 
Inpatient and outpatient claims data and software
from The MEDSTAT Group, Inc. Clinical Perfor-
mance Measurement Workstation (CPMW) prod-
uct were used to find people with diabetes in the
1995 MarketScan data base. CPMW was also used
to estimate for each patient whether the following
seven guideline-based screening and treatment cri-
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teria were met sometime in calendar-year 1996.
CPMW measured whether each patient had at
least:
• Two primary care office visits, one in each half
of 1996;
• One visit with an ophthalmologist;
• Two blood glucose (i.e., hemoglobin A1c)
tests, one in each half of 1996;
• One urinalysis;
• One triglyceride test;
• One total cholesterol test; and
• One HDL cholesterol test.
These criteria were generated as per recommenda-
tions contained in a clinical practice guideline for
diabetes that was first published by the American
Diabetes Association in 1990 [11]. These guide-
line criteria were designed to help control blood
sugar and screen for problems that may lead to
preventable complications such as retinal prob-
lems, kidney disease, heart disease, and other cir-
culatory problems. The two cholesterol tests were
recommended by the ADA to allow easy calcula-
tion of low-density lipoprotein (LDL) cholesterol as
the difference between total and high-density lipo-
protein (HDL) cholesterol. High levels of LDL cho-
lesterol are associated with higher risks of heart dis-
ease, stroke, and other circulatory problems.
The notion that adhering to guidelines will re-
duce these problems is not just a pie-in-the-sky
hope. Others have shown that blood sugar control
and better care may save thousands of lives in the
US and substantially increase quality of life by
limiting blindness, reducing the need for amputa-
tion and preventing end-stage renal disease [12].
 
Statistical Analyses
 
Nonlinear exponential regression models were
used to estimate relationships between medical
care expenditures in 1996 and adherence to the
seven guideline-based measures in that year. The
nonlinear approach was recommended by Mul-
lahy [13], who noted its ability to avoid common
estimation problems that may occur when linear
logarithmic expenditure models (the most com-
mon alternative to the nonlinear approach) are
used. The first of these problems is bias in the
transformation of log dollars back into actual dol-
lars before comparisons are made. This bias can
be avoided by the use of a “smearing estimate”
when retransformation back into actual dollars
is made. However, the application of the smear-
ing estimate often leads to a second important
problem, heteroscedasticity—bias in the standard
errors for the regression-based estimates that may
arise when log linear models are used. Non-linear
estimation approaches with a heteroskedasticity
adjustment can avoid these problems and can
therefore lead to less bias and more accurate esti-
mates of the impact of adherence to a clinical
practice guideline on medical expenditures [13].
Two expenditure regressions were estimated.
The dependent variable for the first regression
analysis was the sum of inpatient and outpatient
expenditures for all medical care services received
in 1996. The second regression focused just on di-
abetes-related expenditures. Diabetes-related ex-
penditures were calculated as the sum of all ex-
penditures for services associated with a primary
or secondary diagnosis of diabetes.
 
Independent Variables for the Regression Analyses
 
The independent variables included in the regression
models served two purposes. First, the indicators of
adherence to the ADA guideline were required to
estimate relationships between adherence and med-
ical care expenditures. Second, additional variables
were included to adjust for measurable differences
between those who were treated according to the
guideline and those who were not.
The major set of independent variables included
seven binary indicators, each coded as 1 when the
patient was treated in a manner consistent with
a guideline-based measure; otherwise each variable
was coded as 0. Additional independent variables in-
cluded binary indicators to differentiate between
type of health plan (with enrollment in an indemnity
plan being the reference category for compari-
sons). Other independent variables adjusted for
age group, gender, urban/rural location, census re-
gion, severity of illness, and spouse/dependent sta-
tus. The rationale for these particular adjustments
is as follows.
We controlled for patient age and gender be-
cause these variables often influence treatment
patterns, and they may be correlated with severity
of illness [14].
Next, we controlled for plan type (e.g., indem-
nity vs. noncapitated point of service or preferred
provider organization managed care plans). Ad-
herence to guidelines may vary by plan type. In
addition, others have argued that managed care
plans may be more attractive to those who are less
severely ill, and hence less costly [15]. Alterna-
tively, managed care plans may be more efficient
than indemnity plans, leading to lower expendi-
tures regardless of adherence to clinical practice
guidelines. Finally, the controls for plan type dif-
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ferentiated between established patients (those who
did not switch plan types between 1995 and 1996)
and those who were new to a plan type in 1996.
Newer patients may be more expensive to treat,
since histories may have to be retaken and other
tests and procedures may be re-done if previous
medical records are not available.
We also controlled for whether the patient was
a spouse or dependent (vs. the major policyholder),
to generate a crude indicator for family size. Patients
from larger families may receive more pressure to
manage disease well or to receive treatment earlier if
problems occur.
Urban vs. rural location and census region were
included as covariates in the regressions because
treatment patterns for diabetes may differ accord-
ing to both large and small geographic areas [2,5].
In addition, the health care utilization and expen-
diture patterns tend to vary between urban and
rural areas in the United States.
Next, some controls for type and severity of ill-
ness were added. The first was an indicator to dif-
ferentiate between insulin-dependent and noninsu-
lin-dependent diabetes. Insulin-dependent patients
were found by looking for claims for insulin some-
time during the study period.
Another control for severity of illness was based
upon Version 4.1 of the Adjusted Clinical Group
(ACG) software. ACGs were formerly known as
Ambulatory Care Groups. The ACG software was
developed at Johns Hopkins University [16]. The
ACG software divided patients into 50 distinct
groups based upon their age, gender, and list of di-
agnoses in the 12 months after identification with
diabetes for our study. The 50 groups have clinical
meaning as correlates with severity of illness. For
example, they differentiated between minor acute
conditions, minor chronic conditions, major acute
conditions, major chronic conditions, and other
clinically relevant features. As a result, ACGs typi-
cally explain much of the variation in health care
expenditures within a sample [16].
Rather than use binary indicators for the 50
ACGs in our regression models, we calculated the
case weight value for each patient’s ACG and used
that value as a correlate of illness severity. The
value of the ACG case weight for each patient was
defined as the average inpatient and outpatient ex-
penditures for 1996 among the patients in his/her
ACG, divided by the average expenditures for the
whole sample of patients. Thus, case weight values
greater or less than 1.0 indicated, proportionately,
how much more or less expensive the patient was
expected to be, compared to all patients in the
sample. If treatment expenditures were correlated
highly with severity of illness, and if the ACG dis-
tributions differed between those who were treated
according to guidelines and those who were not,
using the ACG case weight helped control for dif-
ferences in severity of illness across the sample.
The next control for illness severity was a bi-
nary indicator to denote those patients who were
early retirees. If early retirement was due to health
problems, this variable would serve as a rough
proxy for severity of illness.
The final control for severity of illness incorpo-
rated into the nonlinear regressions was a binary
indicator for whether the patient had a concomi-
tant (coexisting) psychiatric problem noted in his/
her list of diagnoses during the 12 months after
they were first identified for our sample. The ex-
istence of these problems may complicate treat-
ment patterns and the patient’s ability to manage
his/her disease.
Inferences about the statistical significance of the
independent variables in the regression analyses were
based upon robust standard errors that adjusted for
potential heteroscedasticity—a non-constant vari-
ance for the regression residuals. Heteroscedasticity
is often present in expenditure models because dollar
values are truncated at zero but are not truncated
from above, and some sample members may have
very high expenditures. This may lead to non-con-
stant variances for groups of individuals with very
low vs. very high expenditures, and this in turn
would bias the standard errors obtained from the re-
gression analyses. Calculating robust standard errors
is recommended by Davidson and MacKinnon [17]
to avoid this problem, without having to discard the
valuable information provided by those with low
and high expenditure values.
 
Generating Expenditure Predictions
from the Regressions
 
The nonlinear regressions were used to generate
expenditure estimates for 1996 that would allow
fair comparisons of patients who were treated ac-
cording to clinical practice guidelines vs. those who
were not. Adjusted expenditures were found by ap-
plying the results of the regression model to each
member of the sample in seven iterations, one for
each guideline-based measure. This was done by first
assuming that all sample members were treated ac-
cording to one clinical practice guideline-based
measure. Under this scenario, their adjusted expen-
ditures were estimated as follows:
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Adjusted $
 
adhere
 
 
 

 
 exp {coefficient on guideline
measure of interest 
 

 
 sum of (coefficients of other
guidelines * value of other guideline variables) 
 

 
sum of (coefficients of other independent variables
* value of those independent variables)}
Next, it was assumed that none of the sample mem-
bers were treated according to that clinical practice
guideline measure. Under this scenario, adjusted
expenditures were estimated as above, except that
the value of the coefficient of the guideline of inter-
est was ignored. We then used a paired 
 
t
 
-test to test
for differences in the mean values of adjusted ex-
penditures for those who adhered vs. those who did
not adhere to the clinical practice guideline of inter-
est. This whole procedure was then replicated for
the other six guideline measures.
 
Results
 
Sample Characteristics
 
Table 1 notes the distribution of the 18,403 pa-
tients in our sample. Mean expenditure for all in-
patient and outpatient services in 1996 was about
$5,817, roughly 32% of which ($1,840) was for
diabetes-related services.
With regard to clinical practice guideline crite-
ria, Table 1 shows that, with one exception, less
than 44% of the sample members were treated ac-
cording to the guideline-based measures we inves-
tigated. The one exception is that most patients
(74%) had at least two office visits for primary
care in 1996, with one visit in each half of the
year. Thus, there appears to be much room for im-
provement in these care patterns.
Table 1 shows that most patients in our sample
were over age 44 and slightly less than half were
female. These percentages are similar to those re-
ported in national samples by Brechner et al. [2]
and Beckles et al. [3]. About 79% of the Mar-
ketScan sample lived in urban areas, and most re-
sided in the north central US. Roughly one-third
of the sample included spouses or dependents.
With regard to type and severity of illness,
about 21% of the patients were insulin dependent
and 10% of the sample had a psychiatric comor-
bidity. Although not shown in the table, about
50% of the patients had eight or more unique di-
 
Table 1
 
Mean and standard deviation of expenditure variables and predictors
 
Sample Size 
 

 
 18,403
Variable Mean Std Dev.
1996 Total Expenditures 5816.53 15994.47
1996 Diabetes Related Expenditures 1839.99 8282.19
1996 Expenditures Unrelated to Diabetes 3976.54 11436.75
Had at least 2 office visits for primary care, 1 in each half of 1996 0.74 0.44
Had at least one ophthalmology visit in 1996 0.29 0.45
Had at least two hemoglobin A1c tests, 1 in each half of 1996 0.20 0.40
Had at least one urinalysis in 1996 0.38 0.48
Had at least one triglyceride test in 1996 0.15 0.35
Had at least one total cholesterol test in 1996 0.43 0.49
Had at least one HDL cholesterol test in 1996 0.31 0.46
Patient was always enrolled in indemnity plan 0.28 0.45
Patient was always enrolled in POS plan 0.06 0.23
Patient was always enrolled in PPO plan 0.50 0.50
Patient switched from indemnity to managed care plan 0.13 0.33
Patient switched from managed care to indemnity plan 0.01 0.09
Patient switched between POS and PPO plans 0.02 0.15
Age 0–34 0.04 0.20
Age 35–44 0.13 0.34
Age 45–54 0.36 0.48
Age 55–64 0.47 0.50
Patient was female 0.46 0.50
Patient was a spouse or dependent of primary beneficiary 0.33 0.47
Primary beneficiary was salaried employee 0.30 0.46
Patient resided in urban area 0.79 0.41
Patient resided in northeast U.S. 0.12 0.32
Patient resided in north central U.S. 0.50 0.50
Patient resided in southern U.S. 0.22 0.42
Patient resided in western U.S. 0.16 0.36
Patient was insulin dependent 0.21 0.40
Patient had a psychiatric comorbidity 0.10 0.30
Patient was an early retiree 0.30 0.46
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agnoses affecting five or more body systems.
About 30% of the sample were early retirees.
 
Results from Nonlinear Regressions
 
The nonlinear regression models performed rea-
sonably well. Table 2 shows the r-squared values
for the total and diabetes expenditure equations to
be 0.13 and 0.08, respectively, which seems typi-
cal for cross-sectional data. (Unlike linear models,
r-squared values are not bounded by 1.0; higher
values are possible but atypical for cross-sectional
data.) Most of the independent variables had sta-
tistically significant coefficients; these relation-
ships will be noted in more detail below.
With a large number of indicators for treatment
according to the ADA guideline, one might won-
der whether correlations between these indicators
would cause estimation problems. This was not
the case in our analysis. Variance inflation factor
(VIF) tests were used to measure the potential for
estimation problems due to high correlations be-
tween the independent variables. VIF values for
the seven guideline indicators were always less
than 2.0, while experts note little worry unless
values exceed 10.0 [18]. The variance inflation
factors were low because the correlations between
the guideline measures were low. The only indica-
tors with correlations above 0.50 were the three
indicators for having triglyceride tests, total cho-
lesterol tests and HDL cholesterol costs, the latter
two of which are supposed to be conducted to-
gether anyway so that LDL cholesterol can be cal-
culated. Even so, correlations between these three
measures never exceeded 0.58.
Results from the nonlinear regressions are pro-
vided in Table 2. Significantly higher expenditures
were shown, on average for:
• Those who had at least two office visits for
primary care, one in each half of 1996 (com-
pared to those with different visit patterns);
• Those who had at least one urinalysis in 1996
(compared to those without any urinalyses);
• Those who had at least one triglyercide test in
1996 (compared to those without any triglyc-
eride tests); and
• Those who had at least one total cholesterol
test in 1996 (compared to those without any
cholesterol tests).
 
Table 2
 
Results from the nonlinear regression analyses exponential model (
 
n
 
 
 

 
 18,403)
 
Total Expenditures Diabetes Related Expenditures
Variable Coefficient Asymptotic RobustStd. Error† Coefficient
Asymptotic Robust 
Std. Error†
Had at least 2 office visits for primary care, 1 in each half of 1996 0.314* 0.058 0.445* 0.145
Had at least one ophthalmology visit in 1996
 

 
0.132* 0.046
 

 
0.109 0.088
Had at least two hemoglobin A1c tests, 1 in each half of 1996
 

 
0.126* 0.049 0.074 0.093
Had at least one urinalysis in 1996 0.171* 0.045 0.323* 0.087
Had at least one triglyceride test in 1996 0.730* 0.090 1.020* 0.171
Had at least one total cholesterol test in 1996 0.493* 0.053 0.259* 0.111
Had at least one HDL cholesterol test in 1996
 

 
0.794* 0.084
 

 
1.009* 0.172
Patient was always enrolled in POS health plan 
 

 
0.644* 0.129
 

 
1.030* 0.431
Patient was always enrolled in PPO health plan 0.145* 0.064 0.256* 0.132
Patient switched from indemnity to managed care plan
 

 
0.370* 0.088
 

 
0.230 0.167
Switched from managed care plan to indemnity plan
 

 
0.057 0.195 0.396 0.312
Patient switched between PPO/POS plans 0.273 0.175 0.416 0.382
Age 0–34
 

 
0.194 0.106 0.032 0.186
Age 35–44 0.468* 0.062 0.673* 0.107
Age 45–54 0.026 0.053
 

 
0.021 0.114
Patient was Female
 

 
0.110* 0.042
 

 
0.226* 0.084
Patient was a spouse or dependent of primary policy holder 0.126* 0.043 0.261* 0.086
Primary beneficiary was salaried employee
 

 
0.010 0.052
 

 
0.095 0.101
Patient resided in urban area 0.234* 0.053 0.258* 0.103
Patient resided in north central U.S.
 

 
0.412* 0.079
 

 
0.259 0.203
Patient resided in southern U.S.
 

 
0.076 0.074 0.383* 0.174
Patient resided in western U.S.
 

 
0.426* 0.088 0.151 0.192
Patient was insulin dependent 0.597* 0.055 1.173* 0.112
ACG case weight 0.330* 0.011 0.341* 0.022
Patient had a psychiatric comorbidity
 

 
0.216* 0.065
 

 
0.277* 0.125
Patient was an early retiree 0.285* 0.065 0.087 0.138
Constant 7.530* 0.105 5.585* 0.226
Adjusted R-squared 0.128 0.085
Model F-statistic 103.690* 65.510*
 
*Statistically significant (
 
P
 
 
 

 
 .05). †Robust standard errors are adjusted for heteroscedasticity as suggested by Davidson and MacKinnon [17].
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Significantly lower expenditures were shown,
on average for:
• Those who had at least two hemoglobin A1c
tests in 1996, one in each half of the year
(compared to those with different testing pat-
terns);
• Those who had at least one HDL cholesterol
test in 1996 (compared to those without any
HDL tests); and
• Those who had at least one ophthalmology
visit for a dilated eye exam in 1996 (for the
analysis of total expenditures only).
Generally, the same patterns were found whether
examining total expenditures or diabetes-related
expenditures. The exceptions were the findings of
significant relationships between expenditures and
having at least one ophthalmology visit and two
hemoglobin A1c blood sugar tests. The signifi-
cantly lower expenditures for those with these
tests were found only in the analysis of total ex-
penditures, not in the analysis of diabetes-related
expenditures.
Table 2 shows many other variables to be im-
portant predictors of health care expenditures as
well. Compared to those who were always en-
rolled in indemnity plans (the reference category),
both types of expenditures were lower, on aver-
age, for those who were always enrolled in the
point of service (POS) plans. Total expenditures
were significantly lower for those who switched
from an indemnity to a managed care plan. Both
types of expenditures were significantly higher for
those who were always enrolled in a preferred
provider organization (PPO) plan.
Next, compared to older patients (those aged
55–64), expenditures of both types were signifi-
cantly higher for those age 35–44. In addition, fe-
males had significantly lower expenditures than
males on average. Spouses and dependents had
significantly higher expenditures of both types
than primary policy holders.
Next, expenditures of both types were signifi-
cantly higher for those in urban areas. Differences
in expenditures across the census regions were
also noted. Total expenditures were significantly
lower for those in the North Central and Western
regions, compared to those in the Northeastern re-
gion. Diabetes-related expenditures were signifi-
cantly higher for those in the southern US.
Among the variables used to adjust for differ-
ences in severity of illness, we found that both
types of expenditures were higher, on average, for
those who were insulin-dependent, and for those
with higher ACG case weights, as expected. Surpris-
ingly, those who had a psychiatric comorbidity had
significantly lower expenditures, on average, com-
pared to those who did not have such comorbidities.
Finally, those who were early retirees tended to have
higher expenditures than others.
 
Predicted Expenditures and Treatment Patterns
 
Table 3 addresses questions about the cost of ad-
hering to the ADA guideline in a more direct way.
This table shows adjusted expenditure estimates
under two scenarios. The first scenario was based
on the assumption that every patient was treated
or screened according to the seven guideline-based
measures, and the second scenario was based on
the assumption that no one was treated or screened
that way. Thus, the differences between these two
sets of estimates reflect upper bound estimates of
what it may cost to adhere to the seven clinical
practice guideline-based measures in the short run.
The bottom row of Table 3 shows that adher-
ing to these clinical practice guideline-based mea-
 
 
Table 3
 
Estimated total and diabetes related expenditures for those who were and were not treated according to the ADA 
Guideline (based on exponential regression analyses, n  18,403)
 
Estimated total expenditures Estimated diabetes-related expenditures
Guideline measure Adhere toguideline
Do not
adhere Difference
Adhere to 
guideline
Do not
adhere Difference
Had at least 2 primary care office visits, 1 in each half of 1996 5477.97 4197.47 1280.50* 1592.42 1021.19 571.23*
Had at least 1ophthalmology visit in 1996 4933.81 5623.61
 

 
689.80* 1361.71 1517.67
 

 
155.96
Had at least 2 hemoglobin A1c test, one in each half of 1996 4884.03 5540.34
 

 
656.31* 1548.88 1437.52 111.36
Had at least 1 urinalysis in 1996 5935.47 5001.25 934.22* 1745.91 1264.47 481.44*
Had at least 1 triglyceride test in 1996 9963.47 4802.86 5160.61* 3482.44 1256.44 2226.00*
Had at least 1 total cholesterol test in 1996 6936.38 4238.15 2698.23* 1668.79 1287.09 381.70*
Had at least 1 HDL cholesterol test in 1996 3291.46 7283.61
 

 
3992.15* 781.43 2142.91
 

 
1361.48*
Mean value for all seven guidelines 5955.68 5242.33 713.35* 1740.23 1418.18 322.05*
 
*The mean values for those who adhere and those who do not are significantly different (
 
P
 
 
 

 
 .05, paired t-test of predicted values).
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sures costs money in the short run. Total expendi-
tures in 1996 would have been about $713 higher,
on average, if all sample members had been treated
according to guidelines, compared to what expen-
ditures would have been if no one had been treated
that way (i.e., $5955 vs. $5242). Diabetes-related
expenditures would have been about $322 higher,
on average, if everyone had been treated or screened
according the seven guideline-based measures we in-
vestigated (i.e., $1740 vs. $1418).
While in an overall sense the data in Table 3
show that adhering to clinical practice guideline
criteria costs money in the short run, there were
some exceptions. The table also shows that having
at least one HDL cholesterol test in 1996 was as-
sociated with significantly lower total expendi-
tures and diabetes-related expenditures. Having at
least one ophthalmology visit for an eye exam and
having at least two hemoglobin A1c blood sugar
tests were associated with significantly lower total
health expenditures.
 
Conclusion
 
The results of this study are illuminating in at least
four respects.
First, it seems clear that adhering to most of the
clinical practice guideline-based criteria we con-
sidered will cost money in the short-run. If the
analyses controlled well for differences in covari-
ate factors, the results suggest that adhering to these
seven measures would cost about $713 higher, on
average, than not adhering to them, in 1996 dollars.
The $713 figure should be viewed as an upper-
bound estimate. It is based upon simulations as-
suming first that no one was treated according to
guideline criteria, then that everyone was treated
according to those criteria. In reality, many pa-
tients were treated in a manner consistent with at
least one guideline, although the data suggest that
much room for improvement exists with regard to
treatment processes.
If it costs more to treat patients according to the
guideline, what does this mean for health plans, for
patients, and for doctors? It may mean that many
patients are currently being undertreated, or at
least under-monitored. Maybe they should receive
more care, and maybe their expenditures should be
higher. If this is the case, health plans should look
for ways to motivate more appropriate care pat-
terns, and doctors should help motivate patients to
keep appointments to undergo more intensive
monitoring or treatment processes.
Next, the analyses suggest that adhering to the
clinical practice guideline may cost more than just
the cost of the guideline-based visits and tests. As
noted above, those who were treated according to
guideline criteria cost about $713 more, on aver-
age, than those treated in other ways. Once this
result was obtained, we went back to the data to
calculate just the average cost of each physician
visit and test that would be expected if treatment
had been made according to the guideline criteria.
On average, the payments for these visits and tests
amounted to $297 (in 1996 dollars). This $297
dollar figure reflects the average cost of two pri-
mary care physician visits (at $51 each), one visit
to an ophthalmologist for an eye exam ($64), two
hemoglobin A1c tests (at $21 each), one urinalysis
($10), one triglyceride test ($30), one total choles-
terol test ($29), and one HDL cholesterol test
($20).
The difference between the $713 figure first es-
timated and the $297 value of the guideline-based
services is $416. This $416 figure represents the
value of additional services applied during the
same visits when guideline-based services were
provided; these additional services may not other-
wise have been provided. If these were appropriate
and necessary services for diabetes patients to re-
ceive, there may be otherwise hidden advantages
and costs to providing treatment according to clin-
ical practice guidelines. Health plans, doctors, and
patients should consider this point as discussions
about treatment processes occur.
Third, the results show that it may be cheaper
in the short run to deviate from clinical practice
guidelines, but this should not encourage provid-
ers to do so. The ADA guideline [11] and other
guidelines for diabetes treatment [4] were devel-
oped by expert family practitioners and specialists
who conducted systematic and extensive reviews
of the research literature. The results of these re-
views suggested a number of instances in which
better care will lead to better outcomes, especially
in the long run. Examples included better blood
sugar control, more frequent visits to the doctor
for monitoring, and more frequent urinalysis, di-
lated eye exams, triglyceride measurement, and
cholesterol testing than are frequently the case.
One of the most important early studies consid-
ered by the ADA and other guideline developers
was published by the Diabetes Control and Com-
plications Trial Research Group. These authors
noted that intensive blood sugar control (based on
more frequent hemoglobin A1c testing) and more
frequent visits to the physician would reduce poor
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outcomes [19]. In addition, later analyses of data
from that Trial [12] suggest that more intensive
treatment of diabetes could ultimately save 920,000
years of sight, prevent 691,000 years of end-stage
renal disease, save 678,000 years without ampu-
tated limbs, and save 611,000 years of life among
patients in the United States. Thus, we believe that
the short-run costs of adhering to clinical practice
guidelines should be viewed as an investment in
better health in the long term. Deviating from the
ADA clinical practice guideline is likely to be a
penny-wise but pound-foolish approach.
Finally, it is important to note that adherence
to the recommended frequency of hemoglobin A1c
tests was associated with significantly lower total
medical expenditures. The results of hemoglobin
A1c tests provide important information about the
management of diabetes, and about how well pa-
tients may adhere to advice about diet and sugar
intake. Moreover, low blood sugar is the recog-
nized key to preventing both short and long-term
complications from diabetes. Thus, adherence to
this guideline criterion may save money in the
short run and promote substantially better health
in the long run as well. Similar statements can be
made about adhering to the recommended fre-
quencies of having dilated eye exams. These win-
win scenarios for health plans and patients should
not be discounted.
 
Limitations
 
The results of this study should be viewed in the
context of a number of limiting factors. First, we
studied short-term implications of adhering to
clinical practice guideline-based measures. How-
ever, as one of the anonymous reviewers of this
paper pointed out, following patients for longer
than the year we were able to observe them may
help identify cost savings that eventually arise as a
result of better care in earlier years.
Second, the analytic sample was taken from
readily available claims data sources, and only
some indicators of treatment processes can be
measured with claims data. Examples of other im-
portant contributors to good diabetes manage-
ment include effective patient and family educa-
tion and training about diabetes care, successful
weight control measures, and compliance with
suggested care management strategies. The short-
term and long-term cost impact of these factors
should be measured in other studies.
Third, patients could not be assigned randomly
to groups that differed according to treatment by
clinical practice guidelines. Thus, there were mea-
surable, and probably unmeasurable, differences in
patients across the guideline measures we studied.
Nonlinear regression was used to control for the
impact of measurable factors, but the impact of un-
measurable factors may still leave us with unavoid-
able selection bias. Terza [20] recently developed
methods for addressing selection bias in nonlinear
models, but his approach (as well as the available
alternatives) may not be generalized to models with
more than one independent variable (e.g., guideline
measure) that might be the subject of selection bias.
Thus, the results of our study should be viewed as
preliminary until randomized trials are conducted.
Fourth, we did not survey diabetes patients, so
we do not know if those who were treated accord-
ing to guideline recommendations were more sat-
isfied with their care. A recent study by Wasser-
man et al. [21] assessed the quality of care and
patient satisfaction and correlated the two, but
their study focused only on blood sugar control
using frequent hemoglobin A1c measurement. In
that study of 11 health plans in California, Wasser-
man et al. found patient satisfaction to be very high
regardless of whether A1c tests were conducted
(83% of the patients rated the quality of their care
as either excellent, very good, or good). With per-
ceptions of quality being so high, one might not
expect much marginal improvement in satisfaction
as better care is provided, but other researchers
should investigate this issue to find out what mat-
ters most to patients. This may help doctors tailor
treatment strategies or better educate their pa-
tients so that compliance with treatment recom-
mendations is higher and bad outcome rates are
reduced.
Finally, people in 35 health care plans across
the country were studied, but no expenditure data
were available from HMOs or capitated point of
service plans. Thus, it was not possible to include
information about HMOs or capitated point of
service plans in these analyses, and the results are
not generalizable to those plan types.
In light of the study findings and limitations,
the message we wish to convey is summarized as
follows. Adherence to many clinical practice guide-
line-based measures for diabetes is generally low,
and, with some important exceptions, it may be
somewhat costly in the short run. However, deviat-
ing from clinical practice guidelines may be short-
sighted, avoiding many of the short-term benefits
of blood sugar control and regular eye care and
avoiding longer-term benefits of more intensive
treatment that have been identified in other re-
search.
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